Table 2.
Relationship between R-ATG induction therapy development of aggressive PTLD (monomorphic PTLD and Hodgkin lymphoma).
| Aggressive PTLD | Odds ratio | p value | 95% Confidence interval |
|---|---|---|---|
| R-ATG versus IL2-RA | 1.83 | .04 | 1.001 to 3.34 |
| Tacrolimus versus cyclosporine | 0.63 | .17 | 0.32 to 1.22 |
| Sex: | |||
| Male | 1.08 | .78 | 0.61 to 1.89 |
| CMV: | |||
| Positive | 1.14 | .67 | 0.61 to 2.10 |
| EBV: | |||
| Positive | 0.84 | .55 | 0.49 to 1.46 |
| Recipient age | 1.00 | .89 | 0.98 to 1.02 |
| Donor age | 0.98 | .09 | 0.96 to 1.00 |
| HLA mismatch | 0.88 | .09 | 0.75 to 1.02 |
| Steroids maintenance: | |||
| Yes | 0.79 | .53 | 0.38 to 1.64 |
R-ATG: Rabbit antithymocyte globulin; IL2-RA: interleukin-2 receptor antagonist; CMV: Cytomegalovirus; EBV: Epstein-Barr virus; HLA: Human leucocyte antigen.